The US health regulator has provided its final approval to the Glenmark Pharmaceuticals for generic Diclofenac Sodium gel that is used in the treatment of skin lesion.
The company has said in a BSE filing that “Glenmark Pharmaceuticals Ins USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Diclofenac Sodium gel, 3 percent.”
It further said that the product is a generic version of Fougera Pharmaceuticals Inc’s Solaraze gel, 3 percent.
